A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
We studied the effects of 3-carboxy-4-methyl-5-propyl-2-furan-propanoic acid (CMPF), indoxyl sulfate, and hippuric acid on iodide production by rat hepatocytes in primary cultures. We questioned whether these substances could explain the alteration of serum thyroid hormone parameters observed in renal failure. Iodide production from [125I]T4 by rat hepatocytes was significantly inhibited in the presence of serum from uremic patients. Serum concentrations of CMPF, indoxyl sulfate, and hippuric acid were markedly elevated in uremic patients. The minimum concentration that inhibited iodide production, when expressed as a molar ratio of the inhibitor to BSA, was 0.13 for CMPF, 0.53 for indoxyl sulfate, and 1.33 for hippuric acid. This molar ratio was lower than the corresponding mean molar ratio in uremic sera for CMPF (0.38) and indoxyl sulfate (0.63), while it was higher than that found for hippuric acid (0.85). The inhibition was reproduced when the inhibitors were added to normal human serum. The decreased iodide production was not due to the inhibition of deiodinase activity. The deiodination of rT3 by rat liver microsomes was unaffected by these inhibitors. Charcoal adsorption of uremic serum normalized the iodide production by hepatocytes. This normalization coincided with almost complete removal of CMPF and indoxyl sulfate, with a concomitant reduction of the free T4 fraction. Dialysis of uremic serum only partially restored iodide production. Even though indoxyl sulfate and hippuric acid were no longer detectable, a high concentration of CMPF remained in the serum. The serum free T4 fraction remained elevated in uremic patients after dialysis. Our studies indicate that CMPF and indoxyl sulfate in concentrations normally present in the serum of uremic patients inhibit cellular transport and subsequent deiodination of T4. These substances may account for the low total T3 level in uremic patients.
Lim
C F
CF
Department of Internal Medicine III, Erasmus University Medical School, Rotterdam, The Netherlands.
Bernard
B F
BF
de Jong
M
M
Docter
R
R
Krenning
E P
EP
Hennemann
G
G
D000327:Adsorption; D000818:Animals; D001692:Biological Transport / Q000187:drug effects; D002478:Cells, Cultured; D005663:Furans / Q000097:blood / Q000494:pharmacology*; D006626:Hippurates / Q000097:blood / Q000494:pharmacology; D006801:Humans; D007200:Indican / Q000097:blood / Q000494:pharmacology*; D007454:Iodides / Q000378:metabolism*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000628:therapy; D008099:Liver / Q000378:metabolism*; D008297:Male; D011422:Propionates / Q000097:blood / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D006435:Renal Dialysis; D013974:Thyroxine / Q000378:metabolism*; D014511:Uremia / Q000097:blood / Q000378:metabolism*
D005663:Furans; D006626:Hippurates; D007454:Iodides; D011422:Propionates; C041693:3-carboxy-4-methyl-5-propyl-2-furanpropionic acid; D007200:Indican; D013974:Thyroxine; C030514:hippuric acid